Desvenlafaxine Induced Constipation in A Geriatric Patient: A Case Report
Main Article Content
Abstract
India being a developing country has a high burden of Tuberculosis (TB). It is a communicable disease and a major global heath challenge. Considering the impact of this illness on both individual patients and public health, it is critical to comprehend the effectiveness and adverse pharmacological profile of the medications. Although most patients on a daily ATT regimen do not encounter the documented ADRs listed below, doctors and patients should be concerned about them. For example, rifampicin induced discoloration of body fluids is often overlooked as it is "innocuous". Nonetheless, Adverse drug reaction (ADRs) reports on these drugs are scarce in proportion especially in regards to the most common ADRs like antitubercular treatment (ATT) induced chromaturia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Abhilasha, P., Bhatti, N., Joseph, G., & Badyal, D. K. (2024). Sodium Valproate-Induced Hyperammonemia: A Case Series in a Tertiary Care Hospital. Cureus, 16(7).
Barberio, B., Judge, C., Savarino, E. V., & Ford, A. C. (2021). Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 6(8), 638-648.
Hanna-Jairala, I., & Drossman, D. A. (2022). CENTRAL NEUROMODULATORS IN IRRITABLE BOWEL SYNDROME. WHY, HOW AND WHEN. Official journal of the American College of Gastroenterology| ACG, 10-14309.
Hoyer, D. (2020). Targeting the 5-HT system: Potential side effects. Neuropharmacology, 179, 108233.
Jani, B., & Marsicano, E. (2018). Constipation: evaluation and management. Missouri medicine, 115(3), 236.
Karrouri, R., Hammani, Z., Benjelloun, R., & Otheman, Y. (2021). Major depressive disorder: Validated treatments and future challenges. World journal of clinical cases, 9(31), 9350.
Malgaroli, M., Calderon, A., & Bonanno, G. A. (2021). Networks of major depressive disorder: A systematic review. Clinical Psychology Review, 85, 102000.
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., ... & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 30(2), 239-245.
Loschi, J., Minuti, G., dos Santos, A. A., de Lima Antonio, J. A., Abuhab, A., Sommer, C., ... & Zanin, M. E. (2024). Avaliação da Biodisponibilidade Relativa/Bioequivalência entre formulações orais de desvenlafaxina 50 mg, em participantes brasileiros, saudáveis, em condições de jejum e pós-prandial. Brazilian Journal of Health Review, 7(1), 1575-1588. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534829/
Oliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., ... & Serretti, A. (2021). Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: a systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 109, 110266.
Sharma, A., Rao, S. S., Kearns, K., Orleck, K. D., & Waldman, S. A. (2021). Diagnosis, management and patient perspectives of the spectrum of constipation disorders. Alimentary pharmacology & therapeutics, 53(12), 1250-1267.
Vigi Access. World Health Organisation; 2015. Available from:https://www.vigiaccess.org/. [Last accessed on 2024 Aug 23].
Zhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021). The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. The Journal of clinical psychiatry, 82(2), 29169.